Cara Therapeutics, Inc.

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Merck Obtains Global Rights To Hansoh’

Alumis, Inc. planned to raise between $282.4m and $317.7m in the last biopharmaceutical initial public offering in the US during the first half of 2024, but instead grossed $250m on 27 June from the

Drug developers and investors left San Francisco after the recent J.P. Morgan Healthcare Conference feeling optimistic about prospects for returns on biopharmaceutical investments, certain that forthc

Welcome to another edition of Supplemental Filings, where US-based Pink Sheet reporters offer bonus, quick-hit analysis and insight we think you should know about, but didn’t make it into full-length